Clinical Trials
Clinical Trials More...
Health Care Professionals
How using BronkoTest can reduce emergency exacerbations, saving money and improving… More...

Health Care Professionals…

How Using BronkoTest can reduce emergency exacerbations, saving money and improving patients' quality of life'

Helping primary care healthcare professionals make BETTER decisions…

A number of primary care trusts have implemented patient self management schemes using the BronkoTest sputum colour chart.  Typically all patients with two of more exacerbations in the previous year will be given a self management plan, a BronkoTest chart and a supply of medication.

In a recent study in Doncaster, use of the BronkoTest along with assessment of sputum volume and shortness of breath was designed to encourage early initiation of antibiotics by those who needed them while helping avoid antibiotic use by those who did not.  This project, undertaken in conditions of everyday general practice, shows for the first time that use of a sputum colour chart as part of a programme of professional education and patient self-management reduces the occurrence of COPD exacerbations requiring hospital admission bringing a large cost saving. 

A key element in the initiative was the provision of standby antibiotics and steroids which patients could use to start treatment at home.  The increased confidence patients felt in dealing with their condition and in interacting with health professionals contributed to the success achieved.

At least as important are the implications for the natural history of COPD, lung function and quality of life.  Patients with moderate to severe COPD who have frequent exacerbations experience a significantly greater decline in FEV(1) compared with patients with infrequent exacerbations (1). As earlier use of appropriate treatment results in faster resolution of the exacerbation (2), it can be hoped that the long term decline in lung function can be reduced. Also worth considering is the potential impact of the initiative described above on patterns of antibiotic resistance.  If patients whose sputum remains mucoid are encouraged not to take antibiotics, their overall use in the community should fall.

If repeated across the country, it is likely that the initiative described could achieve substantial savings for the NHS.  We have developed a COPD Cost Benefit Model that will allow PCTs to explore the potential impact of a similar simple and inexpensive intervention on COPD admissions. This model allows PCTs to ascertain the potential benefit of using BronkoTest in their population.  Please contact BronkoTest for a demonstration of this model. 







Copyright/Disclaimer | BronkoTest Ltd 2008 | Design by JNZ